ANDRIA DOTSON: Open Payments
NPI 1588365647 · IDAHO FALLS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$435 in 24 payments from 11 companies in 2025. Trend: 2023 $108 · 2024 $633 · 2025 $435
Food & beverage: $435
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| ABBVIE INC. | 4 | $70 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Indivior Inc. | 3 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Corium, LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Boston Scientific Corporation | 1 | $15 |
Products named: VRAYLAR, CAPLYTA, SUBLOCADE, ABILIFY ASIMTUFII, INGREZZA, AUSTEDO XR, REXULTI, Azstarys.
Industry payments across ID — which companies pay providers there.
